A high cure rate characterizes Non-muscle Invasive Bladder Cancer (NMIBC), yet there is a notable risk of recurrence and progression to muscle-invasive disease. Effective NMIBC management involves precise local resection, staging, and a risk-based approach with intravesical agents. The conventional gold standard for intermediate or high-risk NMIBC has long been Transurethral Resection of the Bladder (TURB), followed by intravesical BCG instillations. Unfortunately, BCG treatment fails in approximately half of high-risk patients, leading to persistent or early recurrent NMIBC.
Intense clinical development and back-to-back approval: Which therapy will dominate the hi...
